Skip to main content
. 2019 Jan 16;37(7):559–569. doi: 10.1200/JCO.18.01010

FIG 4.

FIG 4.

Kaplan-Meier curves of (A) invasive disease-free survival (iDFS), (B) distant disease-free survival (D-DFS), and (C) overall survival (OS) according to nodal status and stromal tumor-infiltrating lymphocytes (TILs) dichotomized at the value of 30%. Shaded areas correspond to pointwise 95% CIs. P values correspond to log-rank tests. iDFS estimated 3-year survival for stromal TILs ≥ 30% v < 30% for node negative disease: 92% (95% CI, 0.89 to 0.96) v 88% (95% CI, 0.85 to 0.90); estimated 5-year survival: 88% (95% CI, 0.84 to 0.93) v 81% (95% CI, 0.77 to 0.84). D-DFS estimated 3-year survival for stromal TILs ≥ 30% v < 30% for node-negative disease: 97% (95% CI, 0.95 to 0.99) v 91% (95% CI, 0.88 to 0.83); estimated 5-year survival: 93% (95% CI, 0.89 to 0.96) v 87% (95% CI, 0.84 to 0.90). OS estimated 3-year survival for stromal TILs ≥ 30% v < 30% for node-negative disease: 99% (95% CI, 0.97 to 1.00) v 95% (95% CI, 0.93 to 0.97); estimated 5-year survival: 95% (95% CI, 0.92 to 0.98) v 90% (95% CI, 0.87 to 0.92).